基于曲妥珠单抗联合奈达铂探讨其对人表皮生长因子受体-2阳性乳腺癌疗效及安全性影响的临床研究  

Clinical study on the effect of Trastuzumab combined with Nedaplatin on the efficacy and safety of human Epidermal growth factor receptor-2 positive breast cancer

作　　者：陈建敦 Chen Jiandun(Guangdong Tongjiang Hospital,Foshan,Guangdong 528300,China)

机构地区：[1]广东同江医院,广东佛山528300

出　　处：《首都食品与医药》2023年第21期52-54,共3页Capital Food Medicine

基　　金：佛山市卫生健康局医学科研课题(项目编号:20220346)。

摘　　要：目的基于曲妥珠单抗联合奈达铂探讨其对人表皮生长因子受体-2阳性乳腺癌疗效及安全性影响.方法选取2022年1月-2023年7月收集的HER-2阳性乳腺癌患者80例为研究对象,采用随机数字表法将其分为观察组与对照组.对照组采用曲妥珠单抗治疗,观察组采用曲妥珠单抗联合奈达铂治疗,比较两组治疗前后临床疗效、血清肿瘤标志物变化、血清T细胞亚群水平.结果治疗6个周期后,观察组治疗总有效率(82.50%)、疾病控制率(95.00%)均显著高于对照组(55.00%、77.50%),且差异有统计学意义(P<0.05);治疗前,两组患者血清肿瘤标志物CA153、CEA、ICAM-1水平对比,差异无统计学意义(P>0.05);治疗后,两组患者CA153、CEA、ICAM-1水平均有所降低(P<0.05),且观察组降低水平显著优于对照组;治疗前,两组患者的CD3^(+)、CD4^(+)及CD8^(+)基线值比较,差异无统计学意义(P>0.05);治疗后,对照组患者的CD3^(+)、CD4^(+)均显著高于观察组(P<0.05),对照组的CD8^(+)水平显著低于观察组(P<0.05).结论曲妥珠单抗与顺铂化疗联合治疗能够显著改善患有HER-2阳性乳腺癌的患者的临床疗效.此外,这种联合治疗方案还可以减轻患者体内的免疫抑制和炎性反应程度,对临床治疗具有重要的参考价值.Objective This study aims to investigate the effect of Trastuzumab combined with Nedaplatin on the efficacy and safety of human Epidermal growth factor receptor-2 positive breast cancer.Methods 80 HER-2 positive breast cancer patients collected from January 2022 to July 2023 were selected as the research objects,and randomly divided into the observation group and the control group.The control group was treated with Trastuzumab,and the observation group was treated with Trastuzumab combined with Nedaplatin.The clinical efficacy,changes of serum tumor markers,and levels of serum T cell subsets were compared between the two groups before and after treatment.Results After 6 cycles of treatment,the total effective rate(82.50%)and disease control rate(95.00%)of the observation group were significantly higher than those of the control group(55.00%and 77.50%),and the difference was statistically significant(P<0.05);before treatment,there was no statistically significant difference in the levels of serum tumor markers CA153,CEA,and ICAM-1 between the two groups of patients(P>0.05);after treatment,the levels of CA153,CEA,and ICAM-1 in both groups of patients decreased(P<0.05),and the reduction level in the observation group was significantly higher than that in the control group;before surgery,there was no statistically significant difference in the baseline values of CD3^(+),CD4^(+),and CD8^(+)between the two groups of patients(P>0.05);after operation,the levels of CD3^(+)and CD4^(+)in the control group were significantly higher than those in the observation group(P<0.05),and the levels of CD8^(+)in the control group were significantly lower than those in the observation group(P<0.05).Conclusion The combination of Trastuzumab and cisplatin chemotherapy can significantly improve the clinical efficacy of patients with HER-2 positive breast cancer.In addition,this combination therapy can also reduce the degree of immune suppression and inflammatory response in patients,which has important reference value for clinical treatme

关 键 词：曲妥珠单抗 奈达铂 HER-2阳性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]